A new open-label extension (OLE) study found that 100 mg/day of phosphatidylserine-enriched with docosahexaenoic acid (PS-DHA, Vayacog by Enzymotec Ltd.) might significantly improve or maintain cognitive abilities in elderly individuals with memory complaints, but no dementia. (Dement Geriatr Cogn Disord. 2014;38:39–45).
The OLE study evaluated 122 participants who completed the core study (BMC Neurol. 2011 Jun 28;11:79) over the period of 15 weeks. Sixty-one participants, or continuers, who received 300 mg/day of PS-DHA during the core study, received 100 mg/day of PS-DHA in the OLE. Participants who originally received the placebo, 61 people now referred to as the naïve, also received 100 mg/day of PS-DHA.
Efficacy measurements, including objective reports and subjective measurements, were assessed at the end of the core study (the baseline for the OLE) and the end of the 15-week OLE study. A significant improvement was seen in sustained attention and memory recognition in the PS-DHA naïve group and the PS-DHA continuers maintained the cognitive status seen after the core study.